Monosodium glutamate-induced diabetic mice are susceptible to azoxymethane-induced colon tumorigenesis

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 702-707

  Hata, Kazuya ^a,b   Kubota, Masaya ^a   Shimizu, Masahito ^a   Moriwaki, Hisataka ^a   Kuno, Toshiya ^a   Tanaka, Takuji ^a,c,d   Hara, Akira ^a   Hirose, Yoshinobu ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kamiishidu Division   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; GLUTAMATE SODIUM; SOMATOMEDIN C RECEPTOR;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEWBORN; NONHUMAN; OBESITY; PRIORITY JOURNAL;

EID: 84863291733     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr323     Document Type: Article

References (68)

1. Bergstrom,A. et al. (2001) Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer, 91, 421-430.
2. Murphy,T.K. et al. (2000) Body mass index and colon cancer mortality in a large prospective study. Am. J. Epidemiol., 152, 847-854.
3. Berster,J.M. et al. (2008) Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch. Physiol. Biochem., 114, 84-98.
4. Craigie,A.M. et al. (2011) Study protocol for BeWEL: the impact of a BodyWEight and physicaL activity intervention on adults at risk of developing colorectal adenomas. BMC Public Health, 11, 184.
5. Morita,T. et al. (2005) The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac. J. Cancer Prev., 6, 485-489.
6. Nilsen,T.I. et al. (2001) Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br. J. Cancer, 84, 417-422.
7. Takahashi,H. et al. (2007) Life style-related diseases of the digestive system: colorectal cancer as a life style-related disease: from carcinogenesis to medical treatment. J. Pharmacol. Sci., 105, 129-132.
8. Giouleme,O. et al. (2011) Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J. Gastroenterol., 17, 444-448.
9. Siddiqui,A.A. (2011) Metabolic syndrome and its association with colorectal cancer: a review. Am. J. Med. Sci., 341, 227-231.
10. Canani,R.B. et al. (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J. Gastroenterol., 17, 1519-1528.
11. Herbey,I.I. et al. (2005) Colorectal cancer and hypercholesterolemia: review of current research. Exp. Oncol., 27, 166-178.
12. Chang,C.K. et al. (2003) Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia, 46, 595-607.
13. Davies,M. et al. (2006) The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence. Int. J. Colorectal Dis., 21, 201-208.
14. Durai,R. et al. (2005) The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int. J. Colorectal Dis., 20, 203-220.
15. Sandhu,M.S. et al. (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J. Natl Cancer Inst., 94, 972-980.
16. LeRoith,D. et al. (2003) The insulin-like growth factor system and cancer. Cancer Lett., 195, 127-137.
17. Ewing,G.P. et al. (2010) The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin. Colorectal Cancer, 9, 219-223.
18. Golan,T. et al. (2011) Targeting the insulin growth factor pathway in gastrointestinal cancers. Oncology (Williston Park), 25, 518-526, 529.
19. Ludwig,J.A. et al. (2011) Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers, 3, 3029-3054.
20. Shimizu,M. et al. (2011) Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol. Nutr. Food Res., 55, 832-843.
21. Voskuil,D.W. et al. (2005) The insulin-like growth factor system in cancer prevention: potential of dietary intervention strategies. Cancer Epidemiol. Biomarkers Prev., 14, 195-203.
22. Bustin,S.A. et al. (2001) The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol. Med., 7, 447-454.
23. Haydon,A.M. et al. (2006) Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut, 55, 689-694.
24. Renehan,A.G. et al. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-1353.
25. Shimizu,M. et al. (2009) Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin. Cancer Res., 15, 3068-3075.
26. Shimizu,M. et al. (2008) (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev. Res. (Phila), 1, 298-304.
27. Shimizu,M. et al. (2011) Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev. Res. (Phila), 4, 396-403.
28. Shimizu,M. et al. (2008) EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett., 262, 10-18.
29. Hirose,Y. et al. (2004) Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis, 25, 821-825.
30. Suzuki,R. et al. (2007) Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int. J. Cancer, 120, 252-258.
31. Hayashi,K. et al. (2007) Citrus auraptene suppresses azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db mice. Nutr. Cancer, 58, 75-84.
32. Tanaka,T. et al. (2008) Citrus compounds inhibit inflammation- and obesity-related colon carcinogenesis in mice. Nutr. Cancer, 60 (suppl. 1), 70-80.
33. Nagata,M. et al. (2006) Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. Exp. Anim., 55, 109-115.
34. Sasaki,Y. et al. (2009) Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice. Life Sci., 85, 490-498.
35. Bird,R.P. et al. (2000) The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol. Lett., 112-113, 395-402.
36. Raju,J. (2008) Azoxymethane-induced rat aberrant crypt foci: relevance in studying chemoprevention of colon cancer. World J. Gastroenterol., 14, 6632-6635.
37. Mori,H. et al. (2005) Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem. Biol. Interact., 155, 1-9.
38. Yamada,Y. et al. (2001) Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res., 61, 1874-1878.
39. Yamada,Y. et al. (2003) Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis, 24, 1015-1019.
40. Yamada,Y. et al. (2002) Microadenomatous lesions involving loss of Apc heterozygosity in the colon of adult Apc(Min/+) mice. Cancer Res., 62, 6367-6370.
41. Hata,K. et al. (2006) beta-Catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice. Cancer Lett., 239, 123-128.
42. Mori,H. et al. (2004) Aberrant crypt foci and beta-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat. Res., 566, 191-208.
43. Hirose,Y. et al. (2003) Azoxymethane-induced beta-catenin-accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis, 24, 107-111.
44. Mori,H. et al. (2002) Chemoprevention of large bowel carcinogenesis; the role of control of cell proliferation and significance of beta-cateninaccumulated crypts as a new biomarker. Eur. J. Cancer Prev., 11 (suppl. 2), S71-S75.
45. Hata,K. et al. (2006) Lack of enhancing effects of degraded lambdacarrageenan on the development of beta-catenin-accumulated crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett., 238, 69-75.
46. Gupta,A.K. et al. (2007) Aberrant crypt foci: what we know and what we need to know. Clin. Gastroenterol. Hepatol., 5, 526-533.
47. Takayama,T. et al. (2001) Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology, 121, 599-611.
48. Kukitsu,T. et al. (2008) Aberrant crypt foci as precursors of the dysplasiacarcinoma sequence in patients with ulcerative colitis. Clin. Cancer Res., 14, 48-54.
49. Tanaka,T. (2009) Colorectal carcinogenesis: review of human and experimental animal studies. J. Carcinog., 8, 5.
50. Yasui,Y. et al. (2009) Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets. Curr. Enzym. Inhib., 5, 1-26.
51. Takahashi,H. et al. (2009) Correlation of the plasma level of insulin-like growth factor-1 with the number of aberrant crypt foci in male individuals. Mol. Med. Report, 2, 339-343.
52. Holzwarth-McBride,M.A. et al. (1976) Monosodium glutamate induced lesions of the arcurate nucleus. II. Fluorescence histochemistry of catecholamines. Anat. Rec., 186, 197-205.
53. Nakagawa,T. et al. (2000) Effects of chronic administration of sibutramine on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: relationship of antiobesity effect with monoamines. Exp. Anim., 49, 239-249.
54. Mulholland,H.G. et al. (2009) Glycemic index, glycemic load, and risk of digestive tract neoplasms: a systematic review and meta-analysis. Am. J. Clin. Nutr., 89, 568-576.
55. Pais,R. et al. (2009) Metabolic syndrome and risk of subsequent colorectal cancer. World J. Gastroenterol., 15, 5141-5148.
56. Corpet,D.E. et al. (1997) Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutr. Cancer, 27, 316-320.
57. Tran,T.T. et al. (1996) Insulin promotion of colon tumors in rats. Cancer Epidemiol. Biomarkers Prev., 5, 1013-1015.
58. Bruce,W.R. et al. (2000) Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance. Nutr. Cancer, 37, 19-26.
59. Komninou,D. et al. (2003) Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. (Maywood), 228, 396-405.
60. Corpet,D.E. et al. (1998) Glycemic index, nutrient density, and promotion of aberrant crypt foci in rat colon. Nutr. Cancer, 32, 29-36.
61. Donohoe,C.L. et al. (2011) Visceral adiposity, insulin resistance and cancer risk. Diabetol. Metab. Syndr., 3, 12.
62. Adams,T.E. et al. (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci., 57, 1050-1093.
63. Attia,N. et al. (1998) The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. J. Clin. Endocrinol. Metab., 83, 1467-1471.
64. Hakam,A. et al. (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum. Pathol., 30, 1128-1133.
65. El Yafi,F. et al. (2005) Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clin. Exp. Immunol., 139, 526-533.
66. Jones,J.I. et al. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16, 3-34.
67. Tanaka,T. et al. (2006) Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer, 118, 25-34.
68. Tanaka,T. et al. (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci., 94, 965-973.